Genentech's Aviv Regev discussed the challenges and potential of AI in drug discovery at ICML 2026. She highlighted that while AI has struggled to produce approved drugs, the complexity of biology necessitates AI's integration across the entire R&D pipeline. Regev presented Genentech's "Lab in the Loop" and "Clinic in the Loop" approaches, which use AI to generate molecular data from simple histology images and to model disease progression for better clinical trial design and interpretation. AI
IMPACT AI integration in drug discovery promises to accelerate the development of personalized medicine and overcome biological complexities.
RANK_REASON The article reports on a presentation at a conference discussing the application of AI in drug discovery, rather than a direct product release or research milestone.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
